Jiangsu Aidea Pharmaceutical Group Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
735
- Stock Symbol
-
688488
- Investments
-
4
- Share Price
-
$1.74
- (As of Friday Closing)
Jiangsu Aidea Pharmaceutical Group General Information
Description
Jiangsu Aidea Pharmaceutical Group Co Ltd is engaged in the production and sales of human protein products, and also carries out some generic drug business and distributes Abbott's HIV diagnostic equipment and reagents.
Contact Information
Website
www.aidea.com.cnCorporate Office
- Number 69, Xinganquan West Road
- Hanjiang District
- Yangzhou, Jiangsu 225008
- China
Corporate Office
- Number 69, Xinganquan West Road
- Hanjiang District
- Yangzhou, Jiangsu 225008
- China
Jiangsu Aidea Pharmaceutical Group Stock Performance
As of 13-Nov-2026, Jiangsu Aidea Pharmaceutical Group’s stock price is $1.74. Its current market cap is $731M with 421M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.74 | $1.82 | $1.65 - $3.24 | $731M | 421M | 8.32M |
Jiangsu Aidea Pharmaceutical Group Financials Summary
As of 30-Sep-2026, Jiangsu Aidea Pharmaceutical Group has a trailing 12-month revenue of $104M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,091,638 | 1,006,000 | 465,975 | 723,963 |
| Revenue | 103,991 | 100,005 | 58,227 | 58,144 |
| EBITDA | 6,937 | 13,021 | (13,935) | (5,188) |
| Net Income | 1,033 | (2,716) | (19,679) | (10,752) |
| Total Assets | 285,147 | 273,357 | 256,101 | 246,391 |
| Total Debt | 103,996 | 79,917 | 66,852 | 58,164 |
Jiangsu Aidea Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jiangsu Aidea Pharmaceutical Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Jiangsu Aidea Pharmaceutical Group Patents
Jiangsu Aidea Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026108823-A1 | Amide compound and use thereof | Pending | 19-Nov-2024 | ||
| WO-2026108823-A9 | Amide compound and use thereof | Pending | 19-Nov-2024 | ||
| WO-2026108822-A1 | Amide compound, pharmaceutical composition thereof, and use thereof | Pending | 19-Nov-2024 | ||
| WO-2026108822-A9 | Amide compound, pharmaceutical composition thereof, and use thereof | Pending | 19-Nov-2024 | ||
| EP-4729522-A1 | Crystal forms of sodium salt of polycyclic carbamoylpyridone derivative, and preparation method therefor and use thereof | Pending | 19-Jun-2023 | C07D498/20 |
Jiangsu Aidea Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jiangsu Aidea Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jiangsu Aidea Pharmaceutical Group Investments & Acquisitions (4)
Jiangsu Aidea Pharmaceutical Group’s most recent deal was a Secondary Transaction - Private with NDPharm for . The deal was made on 14-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NDPharm | 14-Jan-2026 | Secondary Transaction - Private | Pharmaceuticals | ||
| Aidi Technology | 07-Jan-2025 | Later Stage VC | Electrical Equipment | ||
| NDPharm | 24-Jul-2024 | Merger/Acquisition | Pharmaceuticals | ||
| NDPharm | 19-Jul-2022 | Secondary Transaction - Private | Pharmaceuticals |
Jiangsu Aidea Pharmaceutical Group ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Jiangsu Aidea Pharmaceutical Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NDPharm | Nanjing, China | 1998 |
Jiangsu Aidea Pharmaceutical Group FAQs
-
When was Jiangsu Aidea Pharmaceutical Group founded?
Jiangsu Aidea Pharmaceutical Group was founded in 2009.
-
Where is Jiangsu Aidea Pharmaceutical Group headquartered?
Jiangsu Aidea Pharmaceutical Group is headquartered in Yangzhou, China.
-
What is the size of Jiangsu Aidea Pharmaceutical Group?
Jiangsu Aidea Pharmaceutical Group has 735 total employees.
-
What industry is Jiangsu Aidea Pharmaceutical Group in?
Jiangsu Aidea Pharmaceutical Group’s primary industry is Drug Discovery.
-
Is Jiangsu Aidea Pharmaceutical Group a private or public company?
Jiangsu Aidea Pharmaceutical Group is a Public company.
-
What is Jiangsu Aidea Pharmaceutical Group’s stock symbol?
The ticker symbol for Jiangsu Aidea Pharmaceutical Group is 688488.
-
What is the current stock price of Jiangsu Aidea Pharmaceutical Group?
As of 13-Nov-2026 the stock price of Jiangsu Aidea Pharmaceutical Group is $1.74.
-
What is the current market cap of Jiangsu Aidea Pharmaceutical Group?
The current market capitalization of Jiangsu Aidea Pharmaceutical Group is $731M.
-
What is Jiangsu Aidea Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Jiangsu Aidea Pharmaceutical Group is $104M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
